← Leaderboards
Shyamasundaran Kottilil
Niaid Extramural Activities
$4,756,982
Attributed
$8,994,439
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,994,439 · 3
By mechanism
U44$6,485,223 · 1
R01$2,296,563 · 1
R44$212,653 · 1
Top collaborators
- Bhawna Poonia7 shared
- Mani Subramanian5 shared
- Pan Zheng1 shared
Most similar at Niaid Extramural Activities
Same institution · by research overlap
Others in their field
Other Emerging Leaders on “Liver Diseases”
- Ionut Bebu · George Washington University$9,972,097
- Barbara Halina Braffett · George Washington University$9,972,097
- Jennifer Cohen Price · University Of California, San Francisco$9,725,541
- Amit Singal · Ut Southwestern Medical Center$9,584,560
- William Raymond Lagor · Baylor College Of Medicine$8,628,302
- William H. Peranteau · Children'S Hosp Of Philadelphia$8,033,995
Research focus
Liver DiseasesImpairmentImmunePharmaceutical PreparationsPreventHepaticMediatingLiverBaseMortalityInfectionImmune ActivationCd4 Positive T LymphocytesResponseHigh RiskCd8-Positive T-LymphocytesHiv InfectionsInflammationInflammatory MarkerImmunityInjecting Drug UserCaringCd8b1 GeneHiv/Hcv
Grant awards (16)
Novel therapy for alcoholic liver disease-associated hepatorenal syndrome$1,499,999
U44 · FY2025 · AA
Novel therapy for alcoholic liver disease-associated hepatorenal syndrome$1,500,000
U44 · FY2024 · AA
Novel therapy for alcoholic liver disease-associated hepatorenal syndrome$1,500,000
U44 · FY2023 · AA
Novel therapy for alcoholic liver disease-associated hepatorenal syndrome$1,000,000
U44 · FY2022 · AA
Novel therapy for alcoholic liver disease-associated hepatorenal syndrome$985,224
U44 · FY2021 · AA
Immune correlates of long-term success with DAA therapy in HCV/HIV infected people who inject drugs$519,525
R01 · FY2021 · DA · contact PI
Immune correlates of long-term success with DAA therapy in HCV/HIV infected people who inject drugs$365,025
R01 · FY2020 · DA · contact PI
Immune correlates of long-term success with DAA therapy in HCV/HIV infected people who inject drugs$154,500
R01 · FY2020 · DA · contact PI
Immune correlates of long-term success with DAA therapy in HCV/HIV infected people who inject drugs$365,853
R01 · FY2019 · DA · contact PI
A randomized, placebo-controlled, single-blinded clinical trial to assess safety and efficacy of CD24Fc in controlling cardiovascular disease risks of HIV-infected patients$212,653
R44 · FY2019 · HL
Immune correlates of long-term success with DAA therapy in HCV/HIV infected people who inject drugs$76,700
R01 · FY2019 · DA · contact PI
Immune correlates of long-term success with DAA therapy in HCV/HIV infected people who inject drugs$371,083
R01 · FY2018 · DA · contact PI
Immune correlates of long-term success with DAA therapy in HCV/HIV infected people who inject drugs$76,700
R01 · FY2018 · DA · contact PI
Immune correlates of long-term success with DAA therapy in HCV/HIV infected people who inject drugs$367,177
R01 · FY2017 · DA · contact PI
Therapeutic Strategies for the Management of HCV/HIV co-$0
Z01 · FY2006 · AI · contact PI
Role Of Innate Immunity In The Initiation And Pathogenes$0
Z01 · FY2006 · AI · contact PI